CELC

Celcuity Inc.

Celcuity is a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity\'s 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient\'s cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies. Celcuity is headquartered in Minneapolis, MN.

Celcuity Inc. (CELC) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A+); its weakest is Profitability (D+). The rating has held at C+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
A+
Factor Score 4.7 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -13.4K
EV / EBITDA -14.0
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -27.2%
Price Return 12M -10.0%
Catalyst Signal 0.00
Market Cap $3.3B
TTM Revenue N/A
Price / Sales N/A
ROE N/M

Historical Factor Score Progression

Held C+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) A+ (4.7) D+ (1.7) D+ (1.7) C+ (2.6) C+ (2.7)
2026-11-04 C+ (2.5) A+ (4.6) D+ (1.7) D+ (1.8) C+ (2.7) C+ (2.7)
2026-10-28 C+ (2.5) A+ (4.6) D+ (1.7) C- (2.0) C+ (2.7) C+ (2.7)
2026-10-21 C+ (2.5) A+ (4.6) D+ (1.7) C- (2.0) C+ (2.6) C+ (2.7)
2026-10-14 C+ (2.5) A+ (4.6) D+ (1.7) C- (2.1) C+ (2.6) C+ (2.7)
Page 1 of 4